The purpose of this study is to assess the safety and tolerability of E5555 in Japanese patients with acute coronary syndrome.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
240
Unnamed facility
Toyoake, Aichi-ken, Japan
Unnamed facility
Safety and tolerability: Adverse events, bleeding events, clinical laboratory tests, Coagulation tests, vital signs and 12-lead ECG.
Time frame: 3 months
Major cardiac adverse events, biomarkers, platelet aggregation inhibition, plasma concentration.
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Placebo tablet taken orally, once a day.
Fukuoka, Fukuoka, Japan
Unnamed facility
Kasuga, Fukuoka, Japan
Unnamed facility
Kitakyushu, Fukuoka, Japan
Unnamed facility
Kurume, Fukuoka, Japan
Unnamed facility
Gifu, Gifu, Japan
Unnamed facility
Ōgaki, Gifu, Japan
Unnamed facility
Fukuyama, Hiroshima, Japan
Unnamed facility
Higashi-Hiroshima, Hiroshima, Japan
Unnamed facility
Hiroshima, Hiroshima, Japan
...and 23 more locations